-+ 0.00%
-+ 0.00%
-+ 0.00%

InnoCare Doses First Patient in Phase III Trial of Mesutoclax Against Venetoclax in AML

PUBT·11/09/2026 01:33:54
Listen to the news
InnoCare Doses First Patient in Phase III Trial of Mesutoclax Against Venetoclax in AML
  • InnoCare Pharma dosed the first patient in a registrational Phase 3 trial in China testing mesutoclax with azacitidine.
  • The study compares the combination against venetoclax with azacitidine in elderly or unfit patients with previously untreated acute myeloid leukemia.
  • Results presented at the 2026 ASCO Annual Meeting showed rapid, deep remissions with no dose-limiting toxicities.
  • Updated results will be presented at the ASH Annual Meeting, scheduled for December 12-15, 2026, in New Orleans.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611082033PRIMZONEFULLFEED9873002) on November 09, 2026, and is solely responsible for the information contained therein.